Share on LinkedInShare on LinkedIn

ARTICLE · 05 DECEMBER 2019

FTC Antitrust Enforcement In Life Sciences Reveals Fissures Among Commissioners

On the flip side, the divide within the FTC arises where pharma mergers meet next-generation antitrust concerns.

United StatesAntitrust/Competition Law

The Federal Trade Commission has promised vigorous antitrust enforcement in life sciences industries, with Chairman Joe Simons promising a "robust program to identify and stop anticompetitive conduct, especially in the nation's critical markets for healthcare." Simons committed that the "agency will continue to monitor this space carefully, and ... will not hesitate to take vigorous action to protect the integrity of US pharmaceutical markets where warranted."

Two recent enforcement actions show that while the five FTC commissioners continue to stand together in enforcing traditional theories of life sciences deals, there appears to be an emerging split along party lines regarding how far to push the boundaries of merger enforcement on newer theories of harm in FTC's life sciences antitrust program.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from